Investments
41Portfolio Exits
1Funds
1Partners & Customers
1Research containing Shinhan Investment Corp.
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Shinhan Investment Corp. in 2 CB Insights research briefs, most recently on Oct 23, 2019.
Latest Shinhan Investment Corp. News
Jun 20, 2022
SK Bioscience shares slide on slow vaccine development 바로가기 기자명 Kim Chan-hyuk 닫기 SK Bioscience, which once made a strong stock market debut in March last year, is now struggling with sliding the price of its shares on Kospi. Analysts said that to boost the stock price struggling to surpass 100,000 won ($77.4), the company has to present investors with detailed achievements from the vaccine business. SK Bioscience shares have recently declined due to the delay in commercialization of Covid-19 vaccine candidate, SKYCovione, analysts said. As of 11:45 a.m. on Monday, shares of SK Bioscience fell 4.4 percent to 99,400 won, considered too low compared to 362,000 won, a 52-week high recorded on Aug. 17 last year. The poor performance of SK Bioscience stocks is attributed to the delay in the commercialization of a Covid-19 vaccine and the overall jittery investor sentiment amid geopolitical issues and inflation worries. At a news conference early this year, SK Bioscience was confident about commercializing and supplying its Covid-19 vaccine. Ahn Jae-yong, CEO of SK Bioscience, said at the news conference that 36 percent of the world’s population was still unvaccinated, adding that the company was actively studying a booster shot. “By the time Korean people get the fourth Covid-19 vaccination, our vaccine will become a ‘weapon’ to protect Korean people’s health,” Ahn said. However, analysts gave a rather dim outlook for SK Bioscience shares. On Thursday, Shinhan Investment released an analyst report and lowered the target price of SK Bioscience by 33 percent to 121,000 won. Shinhan Investment noted that SK Bioscience must have performed well in the second quarter. As a result, the brokerage predicted that the company’s second-quarter sales and operating profit were estimated to be 140.4 billion won and 64.3 billion won, respectively, up 61 percent and 171 percent quarter-to-quarter. In addition, the report said that the company could improve earnings because it resolved the delay in quality assurance of CDMO for Novavax’s Covid-19 vaccine. However, Shinhan Investment lowered the sales outlook for SK Bioscience's Covid-19 vaccine SKYCovione (pipeline name: GBP510), which is about to arrive in the market because countries have excess stocks of existing Covid-19 vaccines and the lower rate of Covid-19 booster shot vaccination in Korea. Also, SKYCovione may not sell as much as the company had expected, both at home and abroad. The first and second dose vaccination rates in Korea were recorded at 87.4 percent and 86.5 percent, respectively. However, the third dose vaccination rate was 64.6 percent, and for the fourth dose, only 8.3 percent, Shinhan Investment said. The report predicted that the total sales of Covid-19 vaccine developers will also plummet from $63.1 billion in 2022 to $33.6 billion in 2023, to $20.1 billion in 2024. Shinhan Investment estimated SKYCovione’s value at 1.25 trillion won, which is lower than a 1.98 trillion won estimate for SKYpack, a 21-valent pneumococcal vaccine candidate that SK Bioscience is jointly developing with Sanofi. “For a rebound in the stock price, the company needs to show high growth in vaccine sales or specific results of facility expansion and entry into new businesses,” the report added. Vaccine industry officials said it became more difficult to expect rapid revenue growth from Covid-19 vaccines. “We will have to see, but the Covid-19 vaccine market has indeed shrunk,” an official at a vaccine maker said. In the worst scenario, developing a Covid-19 vaccine could even hamper a company’s growth, another official said. “SK Bioscience must be frustrated because Covid-19 vaccine development has become like a government project. It can’t give up in the middle of the development,” an official at a biopharmaceutical firm said. “It is also uncertain how much SK Bioscience’s vaccine will be competitive, compared to Pfizer or Moderna vaccine, in other countries,” he added.
Shinhan Investment Corp. Investments
41 Investments
Shinhan Investment Corp. has made 41 investments. Their latest investment was in GGQ Company as part of their Series A on April 4, 2022.
Shinhan Investment Corp. Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/13/2022 | Series A | GGQ Company | $8.95M | Yes | 2 | |
3/2/2022 | Series B | Dr.Diary | $12.22M | Yes | 1 | |
2/8/2022 | Series A | Varram | Yes | 1 | ||
12/16/2021 | Series A | |||||
11/16/2021 | Series A |
Date | 4/13/2022 | 3/2/2022 | 2/8/2022 | 12/16/2021 | 11/16/2021 |
---|---|---|---|---|---|
Round | Series A | Series B | Series A | Series A | Series A |
Company | GGQ Company | Dr.Diary | Varram | ||
Amount | $8.95M | $12.22M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 1 | 1 |
Shinhan Investment Corp. Portfolio Exits
1 Portfolio Exit
Shinhan Investment Corp. has 1 portfolio exit. Their latest portfolio exit was AptaBio on June 12, 2019.
Shinhan Investment Corp. Acquisitions
1 Acquisition
Shinhan Investment Corp. acquired 1 company. Their latest acquisition was Nam An Securities on July 08, 2015.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/8/2015 | Acq - P2P | 1 |
Date | 7/8/2015 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acq - P2P |
Sources | 1 |
Shinhan Investment Corp. Fund History
1 Fund History
Shinhan Investment Corp. has 1 fund, including Shinhan Consumer New Technology Investment Fund No. 2.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Shinhan Consumer New Technology Investment Fund No. 2 | Multi-Stage Venture Capital | Open | 1 |
Closing Date | |
---|---|
Fund | Shinhan Consumer New Technology Investment Fund No. 2 |
Fund Type | Multi-Stage Venture Capital |
Status | Open |
Amount | |
Sources | 1 |
Shinhan Investment Corp. Partners & Customers
1 Partners and customers
Shinhan Investment Corp. has 1 strategic partners and customers. Shinhan Investment Corp. recently partnered with TradeStation on June 6, 2014.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
6/16/2014 | Licensor | United States | In November 2013 , TradeStation and Shinhan Investment Corp. entered into a strategic alliance granting Shinhan Investment Corp. the exclusive right to market , offer and provide to the Korean investor market industry-leading trading technology powered by TradeStation . | 4 |
Date | 6/16/2014 |
---|---|
Type | Licensor |
Business Partner | |
Country | United States |
News Snippet | In November 2013 , TradeStation and Shinhan Investment Corp. entered into a strategic alliance granting Shinhan Investment Corp. the exclusive right to market , offer and provide to the Korean investor market industry-leading trading technology powered by TradeStation . |
Sources | 4 |
Shinhan Investment Corp. Team
1 Team Member
Shinhan Investment Corp. has 1 team member, including current Chief Executive Officer, President, DaeSuk Kang.
Name | Work History | Title | Status |
---|---|---|---|
DaeSuk Kang | Chief Executive Officer, President | Current |
Name | DaeSuk Kang |
---|---|
Work History | |
Title | Chief Executive Officer, President |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.